• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates.1型和2型人类免疫缺陷病毒以及猿猴免疫缺陷病毒分离株的交叉中和作用
J Virol. 1992 Jun;66(6):3602-8. doi: 10.1128/JVI.66.6.3602-3608.1992.
2
Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain.对源自感染减毒猴免疫缺陷病毒(SIV)毒株的恒河猴的恒河猴单克隆抗体所识别的SIV中和表位的鉴定。
Virology. 2001 Nov 10;290(1):59-73. doi: 10.1006/viro.2001.1144.
3
Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope protein.猿猴免疫缺陷病毒包膜蛋白构象依赖性中和表位的研究
J Virol. 1994 Apr;68(4):2624-31. doi: 10.1128/JVI.68.4.2624-2631.1994.
4
Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: recovery from a long-term-nonprogressor SIV-infected macaque.具有高水平同源中和活性的猿猴免疫缺陷病毒(SIV)包膜特异性Fab片段:从长期不进展的SIV感染猕猴中获得
J Virol. 1998 Jan;72(1):585-92. doi: 10.1128/JVI.72.1.585-592.1998.
5
Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains.在豚鼠和恒河猴体内诱导针对1型人类免疫缺陷病毒包膜的抗体:对非致病性和致病性原代分离猿猴/人类免疫缺陷病毒株的中和作用。
J Virol. 2000 Jan;74(1):254-63. doi: 10.1128/jvi.74.1.254-263.2000.
6
The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1.猴免疫缺陷病毒的主要中和决定簇与1型人类免疫缺陷病毒的不同。
Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1418-22. doi: 10.1073/pnas.89.4.1418.
7
Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4.猴免疫缺陷病毒V3环作为抗体介导中和作用靶点的能力:中和敏感性、在巨噬细胞中的生长以及对CD4依赖性降低之间的相关性
J Virol. 2001 Apr;75(8):3903-15. doi: 10.1128/JVI.75.8.3903-3915.2001.
8
Antibodies to V3 loop peptides derived from chimpanzee lentiviruses and the divergent HIV-1ANT-70 isolate in human sera from different geographic regions.来自不同地理区域人类血清中针对源自黑猩猩慢病毒和不同的HIV-1 ANT-70分离株的V3环肽的抗体。
AIDS. 1994 Dec;8(12):1657-61. doi: 10.1097/00002030-199412000-00003.
9
The V3 domain of SIVmac251 gp120 contains a linear neutralizing epitope.猴免疫缺陷病毒251型(SIVmac251)糖蛋白120(gp120)的V3结构域包含一个线性中和表位。
Virology. 1996 Oct 15;224(2):415-26. doi: 10.1006/viro.1996.0548.
10
Comparative studies on neutralisation of primary HIV-1 isolates by human sera and rabbit anti-V3 peptide sera.人血清和兔抗V3肽血清对HIV-1原始分离株中和作用的比较研究。
J Med Virol. 1999 Oct;59(2):169-79.

引用本文的文献

1
Validation of the Viral Barcoding of Simian Immunodeficiency Virus SIVmac239 and the Development of New Barcoded SIV and Subtype B and C Simian-Human Immunodeficiency Viruses.验证猴免疫缺陷病毒 SIVmac239 的病毒条码化以及新条码化的 SIV 和亚型 B、C 猴-人免疫缺陷病毒的开发。
J Virol. 2019 Dec 12;94(1). doi: 10.1128/JVI.01420-19.
2
Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes.理性设计与体内选择编码传播/原始亚型 C HIV-1 包膜的 SHIV。
PLoS Pathog. 2019 Apr 3;15(4):e1007632. doi: 10.1371/journal.ppat.1007632. eCollection 2019 Apr.
3
Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies.广泛中和性HIV-1抗体分离的当前技术简介
Virus Res. 2018 Jan 2;243:75-82. doi: 10.1016/j.virusres.2017.10.011. Epub 2017 Oct 16.
4
Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy.一种由牛痘病毒载体初免- C2V3C3 多肽加强免疫策略引发的强效且广泛反应的 HIV-2 中和抗体。
J Virol. 2010 Dec;84(23):12429-36. doi: 10.1128/JVI.01102-10. Epub 2010 Sep 15.
5
Use of a new dual-antigen enzyme-linked immunosorbent assay to detect and characterize the human antibody response to the human immunodeficiency virus type 2 envelope gp125 and gp36 glycoproteins.使用一种新型双抗原酶联免疫吸附测定法来检测和表征人类对2型人类免疫缺陷病毒包膜糖蛋白gp125和gp36的抗体反应。
J Clin Microbiol. 2006 Feb;44(2):607-11. doi: 10.1128/JCM.44.2.607-611.2006.
6
Protection by live, attenuated simian immunodeficiency virus against heterologous challenge.减毒活猿猴免疫缺陷病毒对异源攻击的保护作用。
J Virol. 1999 Oct;73(10):8356-63. doi: 10.1128/JVI.73.10.8356-8363.1999.
7
Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251.在接受腺病毒-猴免疫缺陷病毒(SIV)包膜初免-gp120加强免疫方案免疫并经阴道用SIVmac251攻击的猕猴中,与疾病进展缓慢相关的因素。
J Virol. 1999 Sep;73(9):7430-40. doi: 10.1128/JVI.73.9.7430-7440.1999.
8
Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus.针对一种异源、非诱导合胞体的原发性人类免疫缺陷病毒的疫苗保护作用。
J Virol. 1998 Dec;72(12):10275-80. doi: 10.1128/JVI.72.12.10275-10280.1998.
9
Identification of the V1 region as a linear neutralizing epitope of the simian immunodeficiency virus SIVmac envelope glycoprotein.将V1区域鉴定为猿猴免疫缺陷病毒SIVmac包膜糖蛋白的线性中和表位。
J Virol. 1997 Dec;71(12):9475-81. doi: 10.1128/JVI.71.12.9475-9481.1997.
10
Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus.细胞培养传代的猿猴免疫缺陷病毒的中和敏感性
J Virol. 1997 Oct;71(10):7895-902. doi: 10.1128/JVI.71.10.7895-7902.1997.

本文引用的文献

1
Human adult T-cell leukemia virus: complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA.人类成人T细胞白血病病毒:整合于白血病细胞DNA中的前病毒基因组的完整核苷酸序列。
Proc Natl Acad Sci U S A. 1983 Jun;80(12):3618-22. doi: 10.1073/pnas.80.12.3618.
2
Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.从艾滋病患者和有患艾滋病风险的人群中频繁检测和分离出细胞病变逆转录病毒(HTLV-III)。
Science. 1984 May 4;224(4648):500-3. doi: 10.1126/science.6200936.
3
Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.从艾滋病患者和艾滋病前期患者中检测、分离并持续生产细胞病变逆转录病毒(HTLV-III)。
Science. 1984 May 4;224(4648):497-500. doi: 10.1126/science.6200935.
4
In vitro generation of an HTLV-III variant by neutralizing antibody.通过中和抗体在体外产生HTLV-III变体。
J Immunol. 1986 Nov 15;137(10):3306-9.
5
Sequence of simian immunodeficiency virus and its relationship to the human immunodeficiency viruses.猿猴免疫缺陷病毒的序列及其与人类免疫缺陷病毒的关系。
Nature. 1987;328(6130):539-43. doi: 10.1038/328539a0.
6
Envelope sequences of two new United States HIV-1 isolates.两种新型美国HIV-1分离株的包膜序列。
Virology. 1988 Jun;164(2):531-6. doi: 10.1016/0042-6822(88)90568-5.
7
Genetic variability between isolates of human immunodeficiency virus (HIV) type 2 is comparable to the variability among HIV type 1.2型人类免疫缺陷病毒(HIV)分离株之间的基因变异性与1型HIV之间的变异性相当。
Proc Natl Acad Sci U S A. 1988 Aug;85(16):5941-5. doi: 10.1073/pnas.85.16.5941.
8
Isolation of T-cell tropic HTLV-III-like retrovirus from macaques.从猕猴中分离出嗜T细胞的HTLV-III样逆转录病毒。
Science. 1985 Jun 7;228(4704):1201-4. doi: 10.1126/science.3159089.
9
HIV-2 antisera cross-neutralize HIV-1.HIV-2抗血清可交叉中和HIV-1。
AIDS. 1988 Apr;2(2):95-100. doi: 10.1097/00002030-198804000-00004.
10
Isolation of a T-lymphotropic retrovirus from naturally infected sooty mangabey monkeys (Cercocebus atys).从自然感染的黑冠白睑猴(Cercocebus atys)中分离出一种嗜T淋巴细胞逆转录病毒。
Proc Natl Acad Sci U S A. 1986 Jul;83(14):5286-90. doi: 10.1073/pnas.83.14.5286.

1型和2型人类免疫缺陷病毒以及猿猴免疫缺陷病毒分离株的交叉中和作用

Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates.

作者信息

Robert-Guroff M, Aldrich K, Muldoon R, Stern T L, Bansal G P, Matthews T J, Markham P D, Gallo R C, Franchini G

机构信息

Laboratory of Tumor Cell Biology, National Cancer Institute, Bethesda, Maryland 20892.

出版信息

J Virol. 1992 Jun;66(6):3602-8. doi: 10.1128/JVI.66.6.3602-3608.1992.

DOI:10.1128/JVI.66.6.3602-3608.1992
PMID:1374810
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC241142/
Abstract

In contrast to infrequent and low-titer cross-neutralization of human immunodeficiency virus type 1 (HIV-1) isolates by HIV-2- and simian immunodeficiency virus (SIV)-positive sera, extensive cross-neutralization of HIV-2NIH-Z, SIVMAC251, and SIVAGM208K occurs with high titer, suggesting conservation of epitopes and mechanism(s) of neutralization. The V3 regions of HIV-2 and SIV isolates, minimally related to the HIV-1 homolog, share significant sequence homology and are immunogenic in monkeys as well as in humans. Whereas the crown of the V3 loop is cross-reactive among HIV-1 isolates and elicits neutralizing antibodies of broad specificity, the SIV and especially HIV-2 crown peptides were not well recognized by cross-neutralizing antisera. V3 loop peptides of HIV-2 isolates did not elicit neutralizing antibodies in mice, guinea pigs, or a goat and together with SIV V3 peptides did not inhibit serum neutralization of HIV-2 and SIV. Thus, the V3 loops of HIV-2 and SIV do not appear to constitute simple linear neutralizing epitopes. In view of the immunogenicity of V3 peptides, the failure of conserved crown peptides to react with natural sera implies a significant role of loop conformation in antibody recognition. Our studies suggest that in addition to their grouping by envelope genetic relatedness, HIV-2 and SIV are neutralized similarly to each other but differently from HIV-1. The use of linear peptides of HIV-2 and SIV as immunogens may require greater attention to microconformation, and alternate subunit approaches may be needed in exploiting these viruses as vaccine models. Such approaches may also be applicable to the HIV-1 system in which conformational epitopes, in addition to the V3 loop, participate in virus neutralization.

摘要

与HIV-2和猴免疫缺陷病毒(SIV)阳性血清对人免疫缺陷病毒1型(HIV-1)分离株的罕见且低效价交叉中和作用相反,HIV-2 NIH-Z、SIV MAC251和SIV AGM208K会发生高效价的广泛交叉中和,这表明中和表位和机制具有保守性。HIV-2和SIV分离株的V3区与HIV-1同源物的相关性最小,但具有显著的序列同源性,并且在猴和人类中都具有免疫原性。虽然V3环的顶部在HIV-1分离株之间具有交叉反应性,并能引发具有广泛特异性的中和抗体,但交叉中和抗血清对SIV尤其是HIV-2的顶部肽识别不佳。HIV-2分离株的V3环肽在小鼠、豚鼠或山羊中均未引发中和抗体,并且与SIV V3肽一起也未抑制HIV-2和SIV的血清中和作用。因此,HIV-2和SIV的V3环似乎并不构成简单的线性中和表位。鉴于V3肽的免疫原性,保守的顶部肽不能与天然血清发生反应,这意味着环构象在抗体识别中具有重要作用。我们的研究表明,除了根据包膜基因相关性进行分类外,HIV-2和SIV彼此之间的中和方式相似,但与HIV-1不同。将HIV-2和SIV的线性肽用作免疫原可能需要更加关注微观构象,并且在将这些病毒用作疫苗模型时可能需要采用替代的亚单位方法。此类方法也可能适用于HIV-1系统,在该系统中,除V3环外,构象表位也参与病毒中和。